AR111131A1 - RECEIVERS OF CHEMICAL ANTIGENS FOR MELANOMA AND USES OF THESE - Google Patents
RECEIVERS OF CHEMICAL ANTIGENS FOR MELANOMA AND USES OF THESEInfo
- Publication number
- AR111131A1 AR111131A1 ARP180100576A ARP180100576A AR111131A1 AR 111131 A1 AR111131 A1 AR 111131A1 AR P180100576 A ARP180100576 A AR P180100576A AR P180100576 A ARP180100576 A AR P180100576A AR 111131 A1 AR111131 A1 AR 111131A1
- Authority
- AR
- Argentina
- Prior art keywords
- melanoma
- genetically modified
- lymphocytes
- compositions
- polynucleotides
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a receptores de antígenos quiméricos (CAR) que comprenden dominios de unión al antígeno que se unen específicamente a células de melanoma, polinucleótidos que codifican dichos CAR, y vectores que comprenden dichos polinucleótidos. Se refiere, además, a células modificadas genéticamente que comprenden dichos polinucleótidos y/o translúcidas con dichos vectores virales y composiciones que incluyen múltiples linfocitos T modificados genéticamente. También se refiere a métodos para producir dichas composiciones y linfocitos T modificados genéticamente y usos (para tratar un melanoma) de dichas composiciones y linfocitos T modificados genéticamente.The present disclosure relates to chimeric antigen (CAR) receptors comprising antigen binding domains that specifically bind to melanoma cells, polynucleotides encoding said CAR, and vectors comprising said polynucleotides. It also refers to genetically modified cells comprising said polynucleotides and / or translucent with said viral vectors and compositions that include multiple genetically modified T lymphocytes. It also refers to methods for producing said compositions and genetically modified T lymphocytes and uses (for treating a melanoma) of said compositions and genetically modified T lymphocytes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470703P | 2017-03-13 | 2017-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111131A1 true AR111131A1 (en) | 2019-06-05 |
Family
ID=67060520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100576A AR111131A1 (en) | 2017-03-13 | 2018-03-13 | RECEIVERS OF CHEMICAL ANTIGENS FOR MELANOMA AND USES OF THESE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR111131A1 (en) |
-
2018
- 2018-03-13 AR ARP180100576A patent/AR111131A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000378A1 (en) | Receptors of chimeric antigens based on single domain antibodies and methods of use of these | |
| CO2017006808A2 (en) | Bcma chimeric antigen receptors | |
| UY37928A (en) | ANTI-CD38 ANTIBODIES AND METHODS OF USE | |
| MX2019001184A (en) | Anti-idiotypic antibodies against anti-cd19 antibodies. | |
| CL2020003031A1 (en) | Psma binding agents and their uses. | |
| CR20170079A (en) | UNION AGENTS TO CD123 AND USES OF THESE | |
| BR112016022369A2 (en) | cd33-specific chimeric antigen receptors for cancer immunotherapy | |
| CL2021000716A1 (en) | Antibody constructs for flt3 and cd3. (divisional sol. 201800269) | |
| AR110676A1 (en) | TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS | |
| CO2017008462A2 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies that specifically bind to cd3 and / or cd123 | |
| AR105433A1 (en) | METHODS TO IMPROVE THE EFFECTIVENESS AND EXPANSION OF IMMUNE CELLS | |
| DOP2019000253A (en) | ANTI-ILT4 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS | |
| EA201792467A1 (en) | HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | |
| BR112018067698A2 (en) | modified cells for immunotherapy | |
| BR112017020894A2 (en) | claudin-18.2 specific immunoreceptors and t-cell epitopes | |
| BR112017020054A2 (en) | antibodies to icos | |
| BR112016019643A2 (en) | cd123 specific antigen chemical receptors for anticancer immunotherapy | |
| CO2018011364A2 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| EA201791139A1 (en) | HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS | |
| AR111288A1 (en) | ANTI-PHF-TAU ANTIBODIES AND ITS USES | |
| CU24494B1 (en) | ANTIBODIES AND CHEMERICAL ANTIGEN RECEPTORS SPECIFIC TO CD19 | |
| BR112017013690A2 (en) | cell | |
| BR112019002579A2 (en) | monovalent, asymmetric and tandem fab bispecific antibodies | |
| MX2020003046A (en) | Anti-hla-a2 antibodies and methods of using the same. | |
| BR112016000666A2 (en) | BISPECIFIC CD3 AND CD19 ANTIGEN BINDING CONSTRUCTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |